Efficacy of avelumab and axitinib depending on disease burden in patients with metastatic renal cell carcinoma: a subgroup analysis of the RAVE-Renal trial
Authors:
- V. A. ChubenkoVCV. A. Chubenko
- O. V. BaklanovaOBO. V. Baklanova
- A. S. KalpinskiyAKA. S. Kalpinskiy
- S. Z. SafinaSSS. Z. Safina
- A. A. LebedinetsALA. A. Lebedinets
- V. V. PetkauVPV. V. Petkau
- E. L. ParsadanovaEPE. L. Parsadanova
- Yu. V. AnzhiganovaYAYu. V. Anzhiganova
- O. Yu. NovikovaONO. Yu. Novikova
- A. O. ShkuratASA. O. Shkurat
Open Access
- 6 August 2025
- journal article
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 21 (2) , 25-32
Abstract
Background. Immunotherapies and targeted therapies have demonstrated significant efficacy in prospective randomized trials establishing them as the standard of care for patients with metastatic renal cell carcinoma.This analysis, part of the RAVE-Renal real-world study, aimed to evaluate the effectiveness of avelumab plus axitinib based on disease burden and the presence of liver and bone metastases.Materials and methods. The RAVE-Renal trial was a multicenter, ambispective study that included treatment-naïve patients with histologically confirmed metastatic renal cell carcinoma and measurable lesions. Patients were treated with avelumab (800 mg every two weeks) and axitinib (5 mg twice daily). Primary endpoints were median progressionfree survival (PFS) and objective response rate (ORR). Secondary endpoints included median overall survival, 1-year overall survival, and safety. Subgroup analyses evaluated median PFS and ORR in patients with ³2 organ metastases, bone metastases, and liver metastases.Results. A total of 125 patients from 13 centers were enrolled, with median follow-up of 16.1 months and median age of 61 years. Based on IMDC (International Metastatic RCC Database Consortium) risk categories, 35.3 % had favorable, 49 % had intermediate, and 15.7 % had poor prognosis. The overall population demonstrated median PFS of 14.9 months and ORR of 44.3 %. Among patients with ³2 organ metastases, median PFS was 13.0 months, and ORR was 36.7 % (all p 0.05). In those with bone metastases, median PFS was 6.5 months (p = 0.160), and ORR was 23.5 % (p = 0.0148). For patients with liver metastases, median PFS was 17.6 months, and ORR was 45.5 % (all p 0.05).Conclusion. The combination of avelumab and axitinib demonstrated consistent efficacy in patients with advanced disease including those with liver and bone metastases. These findings suggest the regimen’s broad applicability and suitability in real-world clinical practice.Keywords
This publication has 20 references indexed in Scilit:
- Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinomaNature Cancer, 2025
- First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 studyCancer Immunology, Immunotherapy, 2025
- Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trialInternational Journal of Cancer, 2024
- A novel anti-FGFR1 monoclonal antibody OM-RCA-01 exhibits potent antitumor activity and enhances the efficacy of immune checkpoint inhibitors in lung cancer modelsImmuno-Oncology and Technology, 2024
- Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101ESMO Open, 2023
- The future landscape of cancer incidence and mortality until 2036 in the Russian Federation.Journal of Clinical Oncology, 2022
- Overall survival in patients with metastatic renal cell carcinoma in Russia, Kazakhstan, and Belarus: a report from the RENSUR3 registryCancer Reports, 2020
- Stereotactic body radiation therapy in combination with systemic therapy for metastatic renal cell carcinoma: a prospective multicentre studyESMO Open, 2019
- Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinomaBMC Medicine, 2016
- Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2007